[Corrigendum] In vitro and in vivo activities of an antitumor peptide HM-3: A special dose-efficacy relationship on an HCT‑116 xenograft model in nude mice

Yassin,Sitelbanat; Hu,Jialiang; Xu,Hanmei; Li,Ce; Setrerrahmane,Sarra

doi:10.3892/or.2020.7503

April-2020 Volume 43 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

April-2020 Volume 43 Issue 4

Full Size Image

Correction Open Access

[Corrigendum] In vitro and in vivo activities of an antitumor peptide HM-3: A special dose-efficacy relationship on an HCT‑116 xenograft model in nude mice

Authors:
- Sitelbanat Yassin
- Jialiang Hu
- Hanmei Xu
- Ce Li
- Sarra Setrerrahmane
View Affiliations / Copyright

Affiliations: The Engineering Research Center of Peptide Drug Discovery and Development, China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China

Copyright: © Yassin et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Pages: 1349-1349
|
Published online on: February 13, 2020

https://doi.org/10.3892/or.2020.7503
Expand metrics +

Article

Oncol Rep 36: [Related article:] 2951-2959, 2016; DOI: 10.3892/or.2016.5077

After the publication of the article, the authors have realized that Figs. 3 and 7 in their paper were published with errors; in the first instance, regarding Fig. 3, panels ‘C’ and ‘D’ contained partially overlapping data and were derived from the same original source, where these images were intended to show the effect of 2 ng/ml sunitinib and 2 µg/ml HM-3, respectively, on cell migration. Likewise, in Fig. 7, panels ‘C’ and ‘D’ also contained partially overlapping data derived from the same original source, even though these images were intended to show representative images for sections of tumor tissue from the HM-3 (3 mg/kg) and HM-3 (48 mg/kg) treatment groups. These errors arose inadvertently, as a consequence of the authors mishandling of their data.

Figure 3.

Inhibitory effect of HM-3 and sunitinib on the migration of HCT-116 cells. (A-G) Representative images for migrated cells in each group. G1, control; G2, sunitinib 0.015 ng/ml; G3, sunitinib 2 ng/ml; G4, HM-3 2 µg/ml; G5, HM-3 16 µg/ml; G6, HM-3 32 µg/ml; and G7, HM-3 64 µg/ml. (H) Migrating cell number of each group. (I) Migration inhibition rate for each group. Mean ± SD, *P<0.05 and **P<0.01, compared with the control group.

Figure 7.

Immunohistochemical analysis of CD31 on the sections of tumor tissues from different groups. (A) Typical image for section from the control group. (B) Typical image for section from sunitinib (60 mg/kg) treatment group. (C) Typical image for section from HM-3 (3 mg/kg) treatment group. (D) Typical image for section from HM-3 (48 mg/kg) treatment group. (E) Comparison of MVD of different groups by counting CD31 positive microvessels. Mean ± SD, **P<0.01, compared with the control group.

The revised versions of Figs. 3 and 7, featuring the corrected data panels for panels ‘C’ and ‘D’ in both Figures, are shown opposite. The revised data shown for these Figures do not affect the overall conclusions reported in the paper. The authors apologize to the Editor of Oncology Reports and to the readership for any inconvenience caused.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

[Corrigendum] In vitro and in vivo activities of an antitumor peptide HM-3: A special dose-efficacy relationship on an HCT‑116 xenograft model in nude mice

This article is mentioned in:

Article

Figure 3.

Figure 7.

Related Articles